The results of this study show that integrin αvβ6, CEA, EGFR, and uPAR are significantly upregulated in pancreatic adenocarcinoma compared to healthy pancreatic tissue and suggest that these biomarkers are promising targets for tumor-specific contrast agent development. The gene discussed is CEACAM3; the disease is pancreatic adenocarcinoma.